129 related articles for article (PubMed ID: 32831024)
21. Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.
Ross LE; Taylor YJ; Richardson LC; Howard DL
J Natl Med Assoc; 2009 Apr; 101(4):316-24. PubMed ID: 19397221
[TBL] [Abstract][Full Text] [Related]
22. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
Li J; Zhao G; Hall IJ
Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake.
Meiser B; Cowan R; Costello A; Giles GG; Lindeman GJ; Gaff CL
Urology; 2007 Oct; 70(4):738-42. PubMed ID: 17991547
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden.
Rönningås U; Fransson P; Holm M; Wennman-Larsen A
BMC Urol; 2019 Jul; 19(1):66. PubMed ID: 31299962
[TBL] [Abstract][Full Text] [Related]
25. Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history.
McDowell ME; Occhipinti S; Gardiner RA; Chambers SK
BJU Int; 2012 Apr; 109 Suppl 3():64-70. PubMed ID: 22458497
[TBL] [Abstract][Full Text] [Related]
26. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
27. Saturation biopsies for prostate cancer detection: effectiveness, safety and predictive factors.
Utrera NM; Sánchez AT; Rodríguez-Antolín A; Martín-Parada A; Lora D; Passas J; González RD
Arch Esp Urol; 2011 Jun; 64(5):421-6. PubMed ID: 21705814
[TBL] [Abstract][Full Text] [Related]
28. Serum prostate-specific antigen levels in older men with or at risk of HIV infection.
Vianna LE; Lo Y; Klein RS
HIV Med; 2006 Oct; 7(7):471-6. PubMed ID: 16925734
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
30. Self-reported prevalence of prostate-specific antigen testing in South Australia: a community study.
Pinnock CB; Weller DP; Marshall VR
Med J Aust; 1998 Jul; 169(1):25-8. PubMed ID: 9695698
[TBL] [Abstract][Full Text] [Related]
31. Investigation of awareness rate of prostate-specific antigen (PSA) among the general public in China and analysis of influencing factors.
Wang Y; Xiao M; Zhang Y; Hong Z; Zhang R; Xu Q; Lin L; Wei Y
Front Public Health; 2023; 11():1080800. PubMed ID: 37213638
[TBL] [Abstract][Full Text] [Related]
32. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
Jonsson H; Holmström B; Duffy SW; Stattin P
Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
[TBL] [Abstract][Full Text] [Related]
33. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
34. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
35. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
36. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah.
Merrill RM
Prev Med; 2001 Dec; 33(6):646-52. PubMed ID: 11716662
[TBL] [Abstract][Full Text] [Related]
37. Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States.
Fedewa SA; Gansler T; Smith R; Sauer AG; Wender R; Brawley OW; Jemal A
Ann Fam Med; 2018 Mar; 16(2):139-144. PubMed ID: 29531105
[TBL] [Abstract][Full Text] [Related]
38. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
39. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
40. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
